Global Radiopharmaceuticals in Nuclear Medicine Market Outlook and Growth Opportunities 2025

Summary

According to APO Research, the global Radiopharmaceuticals in Nuclear Medicine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Radiopharmaceuticals in Nuclear Medicine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Radiopharmaceuticals in Nuclear Medicine market include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Radiopharmaceuticals in Nuclear Medicine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Radiopharmaceuticals in Nuclear Medicine, also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceuticals in Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radiopharmaceuticals in Nuclear Medicine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Radiopharmaceuticals in Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Radiopharmaceuticals in Nuclear Medicine sales, projected growth trends, production technology, application and end-user industry.

Radiopharmaceuticals in Nuclear Medicine Segment by Company

Aurobindo Pharma
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Mundipharma
Novartis
SIEMENS
Bayer
Dongcheng
Eli Lilly
China Isotope & Radiation

Radiopharmaceuticals in Nuclear Medicine Segment by Type

Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals

Radiopharmaceuticals in Nuclear Medicine Segment by Application

Oncology
Cardiology
Other

Radiopharmaceuticals in Nuclear Medicine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Radiopharmaceuticals in Nuclear Medicine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Radiopharmaceuticals in Nuclear Medicine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Radiopharmaceuticals in Nuclear Medicine significant trends, drivers, influence factors in global and regions.
6. To analyze Radiopharmaceuticals in Nuclear Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Radiopharmaceuticals in Nuclear Medicine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiopharmaceuticals in Nuclear Medicine industry.
Chapter 3: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Radiopharmaceuticals in Nuclear Medicine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value (2020-2031)
1.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume (2020-2031)
1.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
2.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
2.2 Radiopharmaceuticals in Nuclear Medicine Industry Drivers
2.3 Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges
2.4 Radiopharmaceuticals in Nuclear Medicine Industry Restraints
3 Radiopharmaceuticals in Nuclear Medicine Market by Company
3.1 Global Radiopharmaceuticals in Nuclear Medicine Company Revenue Ranking in 2024
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Company (2020-2025)
3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Company (2020-2025)
3.4 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Company (2020-2025)
3.5 Global Radiopharmaceuticals in Nuclear Medicine Company Ranking (2023-2025)
3.6 Global Radiopharmaceuticals in Nuclear Medicine Company Manufacturing Base and Headquarters
3.7 Global Radiopharmaceuticals in Nuclear Medicine Company Product Type and Application
3.8 Global Radiopharmaceuticals in Nuclear Medicine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Radiopharmaceuticals in Nuclear Medicine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Radiopharmaceuticals in Nuclear Medicine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Radiopharmaceuticals in Nuclear Medicine Market by Type
4.1 Radiopharmaceuticals in Nuclear Medicine Type Introduction
4.1.1 Diagnostic Radiopharmaceuticals
4.1.2 Therapy Radiopharmaceuticals
4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type (2020-2031)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Type (2020-2031)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type
4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (2020-2031)
4.3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type (2020-2031)
5 Radiopharmaceuticals in Nuclear Medicine Market by Application
5.1 Radiopharmaceuticals in Nuclear Medicine Application Introduction
5.1.1 Oncology
5.1.2 Cardiology
5.1.3 Other
5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application (2020-2031)
5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Application (2020-2031)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application
5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application (2020-2031)
5.3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application (2020-2031)
6 Radiopharmaceuticals in Nuclear Medicine Regional Sales and Value Analysis
6.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2020-2031)
6.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2020-2025
6.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2026-2031)
6.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (2020-2031)
6.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region: 2020-2025
6.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (2026-2031)
6.5 Global Radiopharmaceuticals in Nuclear Medicine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Value (2020-2031)
6.6.2 North America Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value (2020-2031)
6.7.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Value (2020-2031)
6.8.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Value (2020-2031)
6.9.2 South America Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Value (2020-2031)
6.10.2 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2024 VS 2031
7 Radiopharmaceuticals in Nuclear Medicine Country-level Sales and Value Analysis
7.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
7.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025)
7.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Country (2026-2031)
7.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (2020-2031)
7.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (2020-2025)
7.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.5.2 USA Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.9.2 France Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.16.2 China Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.19.2 India Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Aurobindo Pharma
8.1.1 Aurobindo Pharma Comapny Information
8.1.2 Aurobindo Pharma Business Overview
8.1.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.1.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.1.5 Aurobindo Pharma Recent Developments
8.2 Bracco Imaging
8.2.1 Bracco Imaging Comapny Information
8.2.2 Bracco Imaging Business Overview
8.2.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.2.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.2.5 Bracco Imaging Recent Developments
8.3 Cardinal Health
8.3.1 Cardinal Health Comapny Information
8.3.2 Cardinal Health Business Overview
8.3.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.3.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.3.5 Cardinal Health Recent Developments
8.4 Curium Pharma
8.4.1 Curium Pharma Comapny Information
8.4.2 Curium Pharma Business Overview
8.4.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.4.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.4.5 Curium Pharma Recent Developments
8.5 GE Healthcare
8.5.1 GE Healthcare Comapny Information
8.5.2 GE Healthcare Business Overview
8.5.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.5.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.5.5 GE Healthcare Recent Developments
8.6 Jubilant Pharma
8.6.1 Jubilant Pharma Comapny Information
8.6.2 Jubilant Pharma Business Overview
8.6.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.6.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.6.5 Jubilant Pharma Recent Developments
8.7 Lantheus
8.7.1 Lantheus Comapny Information
8.7.2 Lantheus Business Overview
8.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.7.5 Lantheus Recent Developments
8.8 Mundipharma
8.8.1 Mundipharma Comapny Information
8.8.2 Mundipharma Business Overview
8.8.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.8.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.8.5 Mundipharma Recent Developments
8.9 Novartis
8.9.1 Novartis Comapny Information
8.9.2 Novartis Business Overview
8.9.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.9.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.9.5 Novartis Recent Developments
8.10 SIEMENS
8.10.1 SIEMENS Comapny Information
8.10.2 SIEMENS Business Overview
8.10.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.10.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.10.5 SIEMENS Recent Developments
8.11 Bayer
8.11.1 Bayer Comapny Information
8.11.2 Bayer Business Overview
8.11.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.11.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.11.5 Bayer Recent Developments
8.12 Dongcheng
8.12.1 Dongcheng Comapny Information
8.12.2 Dongcheng Business Overview
8.12.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.12.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.12.5 Dongcheng Recent Developments
8.13 Eli Lilly
8.13.1 Eli Lilly Comapny Information
8.13.2 Eli Lilly Business Overview
8.13.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.13.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.13.5 Eli Lilly Recent Developments
8.14 China Isotope & Radiation
8.14.1 China Isotope & Radiation Comapny Information
8.14.2 China Isotope & Radiation Business Overview
8.14.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2020-2025)
8.14.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
8.14.5 China Isotope & Radiation Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
9.1.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Radiopharmaceuticals in Nuclear Medicine Sales Mode & Process
9.2 Radiopharmaceuticals in Nuclear Medicine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
9.2.3 Radiopharmaceuticals in Nuclear Medicine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings